Literature DB >> 29696946

Conventional and advanced magnetic resonance imaging in patients with high-grade glioma.

Whitney B Pope1, Garth Brandal2.   

Abstract

Magnetic resonance imaging is integral to the care of patients with high-grade gliomas. Anatomic detail can be acquired with conventional structural imaging, but newer approaches also add capabilities to interrogate image-derived physiologic and molecular characteristics of central nervous system neoplasms. These advanced imaging techniques are increasingly employed to generate biomarkers that better reflect tumor burden and therapy response. The following is an overview of current strategies based on advanced magnetic resonance imaging that are used in the assessment of high-grade glioma patients with an emphasis on how novel imaging biomarkers can potentially advance patient care.

Entities:  

Mesh：

Year:  2018        PMID： 29696946      PMCID： PMC6123261          DOI： 10.23736/S1824-4785.18.03086-8

Source DB:  PubMed          Journal:  Q J Nucl Med Mol Imaging        ISSN： 1824-4785            Impact factor:   2.346


  100 in total

1.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Authors:  Jerrold L Boxerman; Kathleen M Schmainda; Zheng Zhang; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2015-09-11       Impact factor: 12.300

2.  Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas.

Authors:  Benjamin M Ellingson; Timothy F Cloughesy; Whitney B Pope; Taryar M Zaw; Heidi Phillips; Shadi Lalezari; Phioanh L Nghiemphu; Hassana Ibrahim; Kourosh M Naeini; Robert J Harris; Albert Lai
Journal:  Neuroimage       Date:  2011-10-07       Impact factor: 6.556

3.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

Review 4.  The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.

Authors:  David N Louis; Arie Perry; Guido Reifenberger; Andreas von Deimling; Dominique Figarella-Branger; Webster K Cavenee; Hiroko Ohgaki; Otmar D Wiestler; Paul Kleihues; David W Ellison
Journal:  Acta Neuropathol       Date:  2016-05-09       Impact factor: 17.088

5.  Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma.

Authors:  Daniel A Hamstra; Thomas L Chenevert; Bradford A Moffat; Timothy D Johnson; Charles R Meyer; Suresh K Mukherji; Douglas J Quint; Stephen S Gebarski; Xiaoying Fan; Christina I Tsien; Theodore S Lawrence; Larry Junck; Alnawaz Rehemtulla; Brian D Ross
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-02       Impact factor: 11.205

6.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

7.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

8.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis.

Authors:  Whitney B Pope; Jenny H Chen; Jun Dong; Marc R J Carlson; Alla Perlina; Timothy F Cloughesy; Linda M Liau; Paul S Mischel; Phioanh Nghiemphu; Albert Lai; Stanley F Nelson
Journal:  Radiology       Date:  2008-10       Impact factor: 11.105

9.  Time-delayed contrast-enhanced MRI improves detection of brain metastases and apparent treatment volumes.

Authors:  Marina Kushnirsky; Vinh Nguyen; Joel S Katz; Jared Steinklein; Lisa Rosen; Craig Warshall; Michael Schulder; Jonathan P S Knisely
Journal:  J Neurosurg       Date:  2015-09-11       Impact factor: 5.115

10.  Prediction of methylguanine methyltransferase promoter methylation in glioblastoma using dynamic contrast-enhanced magnetic resonance and diffusion tensor imaging.

Authors:  Sung Soo Ahn; Na-Young Shin; Jong Hee Chang; Se Hoon Kim; Eui Hyun Kim; Dong Wook Kim; Seung-Koo Lee
Journal:  J Neurosurg       Date:  2014-06-20       Impact factor: 5.115
View more
  15 in total

1.  Nuclear Medicine Imaging Procedures in Oncology.

Authors:  Ajay-Mohan Mohan; Nicola Beindorff; Winfried Brenner
Journal:  Methods Mol Biol       Date:  2021

2.  Repeatability of radiotherapy dose-painting prescriptions derived from a multiparametric magnetic resonance imaging model of glioblastoma infiltration.

Authors:  Caterina Brighi; Niels Verburg; Eng-Siew Koh; Amy Walker; Cathy Chen; Sugendran Pillay; Philip C de Witt Hamer; Farhannah Aly; Lois C Holloway; Paul J Keall; David E J Waddington
Journal:  Phys Imaging Radiat Oncol       Date:  2022-06-11

Review 3.  Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.

Authors:  Fabrício Guimarães Gonçalves; Sanjeev Chawla; Suyash Mohan
Journal:  J Magn Reson Imaging       Date:  2020-03-19       Impact factor: 4.813

Review 4.  Radiomics in radiation oncology-basics, methods, and limitations.

Authors:  Philipp Lohmann; Khaled Bousabarah; Mauritius Hoevels; Harald Treuer
Journal:  Strahlenther Onkol       Date:  2020-07-09       Impact factor: 3.621

5.  Stratifying Brain Tumour Histological Sub-Types: The Application of ATR-FTIR Serum Spectroscopy in Secondary Care.

Authors:  James M Cameron; Christopher Rinaldi; Holly J Butler; Mark G Hegarty; Paul M Brennan; Michael D Jenkinson; Khaja Syed; Katherine M Ashton; Timothy P Dawson; David S Palmer; Matthew J Baker
Journal:  Cancers (Basel)       Date:  2020-06-27       Impact factor: 6.639

Review 6.  GliMR: Cross-Border Collaborations to Promote Advanced MRI Biomarkers for Glioma.

Authors:  Patricia Clement; Thomas Booth; Fran Borovečki; Kyrre E Emblem; Patrícia Figueiredo; Lydiane Hirschler; Radim Jančálek; Vera C Keil; Camille Maumet; Yelda Özsunar; Cyril Pernet; Jan Petr; Joana Pinto; Marion Smits; Esther A H Warnert
Journal:  J Med Biol Eng       Date:  2020-12-03       Impact factor: 2.213

Review 7.  Epidemiology of Anthropometric Factors in Glioblastoma Multiforme-Literature Review.

Authors:  Donata Simińska; Jan Korbecki; Klaudyna Kojder; Patrycja Kapczuk; Marta Fabiańska; Izabela Gutowska; Anna Machoy-Mokrzyńska; Dariusz Chlubek; Irena Baranowska-Bosiacka
Journal:  Brain Sci       Date:  2021-01-16

8.  Clinical, radiological and molecular characterization of intramedullary astrocytomas.

Authors:  Laetitia Lebrun; Barbara Meléndez; Oriane Blanchard; Nancy De Nève; Claude Van Campenhout; Julie Lelotte; Danielle Balériaux; Matteo Riva; Jacques Brotchi; Michaël Bruneau; Olivier De Witte; Christine Decaestecker; Nicky D'Haene; Isabelle Salmon
Journal:  Acta Neuropathol Commun       Date:  2020-08-08       Impact factor: 7.801

Review 9.  Molecular and Cellular Complexity of Glioma. Focus on Tumour Microenvironment and the Use of Molecular and Imaging Biomarkers to Overcome Treatment Resistance.

Authors:  Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco
Journal:  Int J Mol Sci       Date:  2020-08-06       Impact factor: 5.923

10.  Phase II trial of proton therapy versus photon IMRT for GBM: secondary analysis comparison of progression-free survival between RANO versus clinical assessment.

Authors:  Karine A Al Feghali; James W Randall; Diane D Liu; Jeffrey S Wefel; Paul D Brown; David R Grosshans; Sarah A McAvoy; Maguy A Farhat; Jing Li; Susan L McGovern; Mary F McAleer; Amol J Ghia; Arnold C Paulino; Erik P Sulman; Marta Penas-Prado; Jihong Wang; John de Groot; Amy B Heimberger; Terri S Armstrong; Mark R Gilbert; Anita Mahajan; Nandita Guha-Thakurta; Caroline Chung
Journal:  Neurooncol Adv       Date:  2021-06-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.